Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Casdatifan (Primary) ; Volrustomig (Primary)
  • Indications Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms ARC-20
  • Sponsors Arcus Biosciences

    • Most Recent Events

    • 02 Oct 2024 According to an Arcus Biosciences media release, the company announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan (AB521), in combination with volrustomig.
    • 03 Jun 2024 Number of treatment arms increased from 7 to 9 by the addition of Experimental: Dose Escalation Cohort 5 and Dose Expansion Cohort 4 (AB521 orally with Cabozantinib) arms. Locally advanced ccRCC is also included now. Patient enrollment is increased.
    • 03 Jun 2024 Planned number of patients changed from 146 to 302.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top